CClinicalTrials.gg
CompletedNCT03803488Updated Jan 14, 2019

Simulated Clinical Use Testing on the DropSafe Safety Pen Needle

An interventional study of DropSafe safety pen needle in Needle Stick, sponsored by HTL-Strefa S.A.. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by HTL-Strefa S.A. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A simulated clinical use testing on the DropSafe safety pen needle

Read the detailed description

This study aims to evaluate the safety of the use of DropSafe safety pen needle in the prevention of needle stick injuries (NSI) and to evaluate the user's satisfaction with regards to the handling characteristics of the product.

02

Conditions studied

  • Needle Stick

Browse trials for

Keywords

  • needlestick
  • needlestick injury
  • pen needle
  • sharps injury prevention
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Minimum of age 18.
  2. Able to understand and provide signed consent for the study.
  3. Willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
  4. Have no concerns about the ability to perform the simulated injections.
  5. Have no financial interest in the sponsor (HTL-Strefa S.A.) or the MRO (NAMSA).

Exclusion criteria

Exclusion Criteria:

  1. If in the opinion of the sponsor or MRO, including the observer/monitor, the potential evaluator is not a good candidate for the study, including for reasons such as mental health.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    simulation of injection

    The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.

    Device: DropSafe safety pen needle

Interventions

  • DeviceDropSafe safety pen needle
05

What researchers measure

Primary outcomes

  1. The true failure rate of DropSafe safety pen needle.

    The failure rate of the safety feature for the DropSafe safety pen needle was estimated using the proportion of devices that fail out of the total tested. Failure was defined as NSI or contact with the needle after injection or non-complete activation of the safety feature.

    Time frame: At time of testing, about an hour

Secondary outcomes

  1. Ease of use

    Evaluator questionnaire using five-point response scale (strongly disagree - strongly agree)

    Time frame: At time of testing, about an hour

  2. Ability to follow the instructions for use

    Evaluator questionnaire using five-point response scale (strongly disagree - strongly agree)

    Time frame: At time of testing, about an hour

  3. Ease of understanding the instructions for use

    Evaluator questionnaire using five-point response scale (strongly disagree - strongly agree)

    Time frame: At time of testing, about an hour

  4. Problems associated with the device

    Evaluator questionnaire using five-point response scale (strongly disagree - strongly agree)

    Time frame: At time of testing, about an hour

06

Study locations

2 sites
  • NAMSA
    Golden Valley, Minnesota 55422, United States
  • NAMSA
    Minneapolis, Minnesota 55426, United States
07

Registry details

Key details

Study ID
NCT03803488
Lead sponsor
HTL-Strefa S.A.
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Sep 28, 2016
Primary completion
Dec 9, 2016
Completion
Dec 9, 2016
Last update
Jan 14, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion